The case for & against
Bull & Bear analysis
Bearish
Alumis Inc. (NASDAQ: ALMS) is an emerging biopharmaceutical company primarily focused on developing therapies for autoimmune diseases, with its leading candidate being envudeucitinib, a TYK2 inhibitor aimed at treating moderate-to-severe plaque psoriasis. As the healthcare industry increasingly shifts toward precision medicine and targeted therapies, Alumis positions itself within a growing trend, which has the potential to elevate its market presence amid evolving treatment paradigms.
Bull says
- ↑Envudeucitinib ONWARD3 trial: 75% PASI 90 & 54% PASI 100 at 48 weeks
- ↑$502.3M cash & equivalents support operations into Q4 2027
- ↑Q4 2026 NDA submission expected, offering regulatory catalyst
- ↑Strong price momentum and high institutional ownership boost confidence
- ↑$40.30 average analyst price target implies upside
- ↑Robust equity profile provides downside support despite losses
Bear says
- ↓Q2 2026 revenue $1.7M down 37% YoY vs. $3.47M consensus
- ↓Net loss $142.2M & EPS $(1.11) missed by $(0.40)
- ↓Leverage elevated; heavy debt load threatens flexibility
- ↓Negative earnings yield and weak profitability factors dampen returns
- ↓FY 2026 revenue estimates cut 13%, signaling slowing growth
- ↓9.6% share drop, insider selling & high short interest reflect bearish sentiment
Investment themes with ALMS
Pharmaceuticals↓ -0.48%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX